| Metric | Value | Detail |
|---|---|---|
| Revenue | $36.8B | +10.0% YoY |
| Net income | $7.7B | 21.0% margin |
| Gross margin | n/a | Gross profit / revenue |
| Operating margin | 24.7% | Operating income / revenue |
| Return on equity | 89% | Net income / equity |
| Return on assets | 9% | Net income / assets |
| Revenue growth (YoY) | +10.0% | FY2024 to FY2025 |
| Revenue 3-yr CAGR | +11.8% | Compound annual |
| Diluted EPS | $14.33 | FY2025 |
| Debt-to-equity | 6.31 | Long-term debt / equity |
| Current ratio | 1.14 | Current assets / liabilities |
| Cash & equivalents | $9.1B | Balance sheet |
| Total assets | $90.6B | FY2025 year-end |
| Shareholders’ equity | $8.7B | FY2025 year-end |
| Share price | $363.39 | Delayed · 2026-07-10 |
| Market cap | $196.1B | Price × shares outstanding |
| P/E ratio | 25.4 | Market cap / net income |
| P/S ratio | 5.3 | Market cap / revenue |
| Dividend yield | 2.66% | Dividend / price |
Stock fundamentals · FY2025 · SEC 10-K data
Amgen Inc. (AMGN) stock fundamentals
Amgen Inc. (AMGN) reported $36.8B in revenue and $7.7B in net income in fiscal 2025, a 21.0% net margin, per its latest SEC 10-K filing. It carries a market capitalization of about $196.1B at a delayed share price. It scores 62/100 on WealthyBud's Investor Score, ranking #26 of 100 covered companies. Score is research, not investment advice.
Revenue (FY2025)
$36.8B
▲ +10.0% YoY
Net income
$7.7B
21.0% net margin
Market cap
$196.1B
Price $363.39 · delayed
P/E ratio
25.4
Price / earnings
Return on equity
89%
Net income / equity
Investor Score
62/100
#26 of 100 covered
Amgen Inc. fundamentals at a glance
The table summarizes Amgen Inc.'s key financial figures for fiscal 2025 — revenue, profitability, returns, growth and balance-sheet strength — each taken from the company's SEC 10-K filing.
How profitable is Amgen Inc.?
Amgen Inc. runs a 21.0% net margin and n/a gross margin in fiscal 2025, turning $36.8B of revenue into $7.7B of profit. Return on equity is 89% and return on assets 9%.
Is Amgen Inc. growing?
Amgen Inc.'s revenue changed +10.0% in fiscal 2025 and compounded at +11.8% a year over three years, reaching $36.8B. Diluted earnings per share were $14.33 for the year.
| Fiscal year | Revenue | Growth |
|---|---|---|
| 2021 | $26.0B | n/a |
| 2022 | $26.3B | +1.3% |
| 2023 | $28.2B | +7.1% |
| 2024 | $33.4B | +18.6% |
| 2025 | $36.8B | +10.0% |
How is Amgen Inc. valued?
Amgen Inc. carries a market capitalization of $196.1B at a delayed share price of $363.39, trading at a 25.4 price-to-earnings ratio and 5.3 price-to-sales with a 2.66% dividend yield. Its Value subscore is 57/100 across the covered universe.
How financially healthy is Amgen Inc.?
Amgen Inc. ended fiscal 2025 with $9.1B in cash, a debt-to-equity ratio of 6.31 and a current ratio of 1.14. Lower leverage and a current ratio above 1.0 signal a stronger balance sheet.
What is Amgen Inc.'s Investor Score?
Amgen Inc. scores 62/100 on WealthyBud's Investor Score, #26 of 100 covered companies as of 2026-07-10. The score blends growth, profitability, returns on capital, balance-sheet strength and value into one percentile. It is a research opinion, not investment advice.
Investor Score
62/100
#26 of 100 covered companies
Subscores are percentile ranks (0–100) across the 100 covered companies, computed from the SEC fundamentals and delayed market price cited on this page. Data-derived opinion, not investment advice.
Amgen Inc. (AMGN) stock FAQ
How much revenue does Amgen Inc. make?
Amgen Inc. (AMGN) reported $36.8B in revenue in fiscal 2025, +10.0% versus the prior year, according to its SEC 10-K filing. Over the past three years its revenue has compounded at +11.8% a year.
Is Amgen Inc. profitable?
Yes. Amgen Inc. earned $7.7B in net income in fiscal 2025, a 21.0% net margin. Its return on equity was 89% and return on assets 9%, based on figures from its latest 10-K.
How fast is Amgen Inc. growing?
Amgen Inc.'s revenue changed +10.0% year over year in fiscal 2025 and compounded at +11.8% annually over three years. Growth is one of four inputs to its WealthyBud Investor Score, scored 78/100 versus the covered universe.
What is Amgen Inc.'s market cap and P/E ratio?
Amgen Inc. has a market capitalization of $196.1B at a delayed share price of $363.39, trading at a price-to-earnings ratio of 25.4 and price-to-sales of 5.3. Its dividend yield is 2.66%. Prices are delayed and illustrative.
What is Amgen Inc.'s WealthyBud Investor Score?
Amgen Inc. scores 62/100, ranking #26 of 100 covered companies as of 2026-07-10. The score is a percentile blend of growth (78), profitability (58), returns on capital (74), balance-sheet strength (28) and value (57). It is a research opinion, not investment advice.
Where does this Amgen Inc. financial data come from?
Fundamentals come from Amgen Inc.'s annual report (Form 10-K) filed with the SEC, via the public-domain EDGAR database. The share price used for market cap, P/E and yield is a delayed end-of-day quote, shown as illustrative; a production site would use a licensed real-time market-data feed.
Fundamentals are drawn from Amgen Inc.’s FY2025 Form 10-K filed with the
SEC (EDGAR, public domain), retrieved 2026-07-10. Share price is a delayed end-of-day quote; market cap, P/E, P/S
and dividend yield are illustrative and not real-time. The Investor Score is a data-derived research opinion.
Not investment advice.